Kelly M. Craft

Kelly M. Craft

Auto-generated profile, based on publicly available information

Kelly M. Craft

Department of Chemistry , Vanderbilt University , 7330 Stevenson Center , Nashville , Tennessee 37235 , United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2019 in MedChemComm
Verified
Journal Article
Closed access
PDF file
KCKelly M. Craft
Kelly M. Craft
JNJohny M. Nguyen
Johny M. Nguyen
LBLawrence J. Berg
Lawrence J. Berg
STSteven D. Townsend
Steven D. Townsend
Staphylococcus aureus (S. aureus) is an asymptomatic colonizer of 30% of all human beings. While generally benign, antibiotic resistance contributes to the success of S. aureus as a human pathogen. Resistance is rapidly evolved through a wide portfolio of mechanisms including horizontal gene transfer and chromosomal mutation. In addition to traditional resistance mechanisms, a special feature of S. aureus pathogenesis is its ability to survive on both biotic and abiotic surfaces in the biofilm state. Due to this characteristic, S. aureus is a leading cause of human infection. Methicillin-resistant S. aureus (MRSA) in particular has emerged as a widespread cause of both community- and hospital-acquired infections. Currently, MRSA is responsible for 10-fold more infections than all multi-drug resistant (MDR) Gram-negative pathogens combined. Recently, MRSA was classified by the World Health Organization (WHO) as one of twelve priority pathogens that threaten human health. In this targeted mini-review, we discuss MRSA biofilm production, the relationship of biofilm production to antibiotic resistance, and front-line techniques to defeat the biofilm-resistance system.

2 December 2017 in ACS Infectious Diseases
Verified
Journal Article
Closed access
DADorothy L. Ackerman
Dorothy L. Ackerman
KCKelly M. Craft
Kelly M. Craft
RDRyan Doster
Ryan Doster
JWJör̈n-Hendrik Weitkamp
Jör̈n-Hendrik Weitkamp
DADavid Aronoff
David Aronoff
STSteven D. Townsend
Steven D. Townsend

14 February 2019 in Accounts of Chemical Research
Verified
Journal Article
Open access
KCKelly M. Craft
Kelly M. Craft
STSteven D. Townsend
Steven D. Townsend
This Account describes the risky proposition of organizing a multidisciplinary team to interrogate a challenging problem in chemical biology: characterizing how human milk, at the molecular level, protects infants from infectious diseases. At the outset, our initial hypothesis was that human milk oligosaccharides (HMOs) possess antimicrobial and antivirulence activities. Early on, we discovered that HMOs do indeed modulate bacterial growth and biofilm production for numerous bacterial pathogens. In light of this discovery, three priorities emerged for our program moving forward. The first was to decode the mode of action behind this activity. The second was to decipher the functional effects of HMO structural diversity as there are ca. 200 unique HMOs present in human milk. Finally, we set our sights on discovering novel uses for HMOs as we believed this would uniquely position our team to achieve a major breakthrough in human health and wellness. Through a combination of fractionation techniques, chemical synthesis, and industrial partnerships, we have determined the identities of several HMOs with potent antimicrobial activity against the important neonate pathogen Group B Streptococcus (Group B Strep; GBS). In addition to a structure–activity relationship (SAR) study, we observed that HMOs are effective adjuvants for intracellular-targeting antibiotics against GBS. This included two antibiotics that GBS has evolved resistance to. At their half maximal inhibitory concentration (IC50), heterogeneous HMOs reduced the minimum inhibitory concentration (MIC) of select antibiotics by up to 32-fold. Similarly, we observed that HMOs potentiate the activity of polymyxin B (Gram-negative-selective antibiotic) against GBS (Gram-positive species). Based on these collective discoveries, we hypothesized that HMOs function by increasing bacterial cell permeability, which would be a novel mode of action for these molecules. This hypothesis was validated as HMOs were found to increase membrane permeability by around 30% compared to an untreated control. The question that remains is how exactly HMOs interact with bacterial membranes to induce permeability changes (i.e., through promiscuous insertion into the bilayer, engagement of proteins involved in membrane synthesis, or HMO-capsular polysaccharide interactions). Our immediate efforts in this regard are to apply chemoproteomics to identify the molecular target(s) of HMOs. These investigations are enabled through manipulation of HMOs produced via total synthesis or enzymatic and whole-cell microbial biotransformation.

2 August 2018 in ACS Chemical Biology
Verified
Journal Article
Closed access
KCKelly M. Craft
Kelly M. Craft
JGJennifer A. Gaddy
Jennifer A. Gaddy
STSteven D. Townsend
Steven D. Townsend


15 November 2017 in ACS Infectious Diseases
Verified
Journal Article
Closed access
KCKelly M. Craft
Kelly M. Craft
STSteven D. Townsend
Steven D. Townsend